Luis E. Fayad

Peer-Reviewed Articles

1. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
2. Wu SY, Damron EP, Xu J, Fang PQ, Dai J, Nair R, Malpica Castillo LE, Fayad LE, Torres-Cabala CA, Medeiros LJ, Vega F, Miranda RN, Duvic M, Pinnix CC, Dabaja BS, Iyer SP, Huen AO, Gunther JR. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol. e-Pub 2024. PMID: 38955474.
3. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
4. Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma 65(5):1-5, 2024. e-Pub 2024. PMID: 38248629.
5. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2023. PMID: 37985359.
6. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
7. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw 21(11):1118-1131, 2023. PMID: 37935098.
8. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
9. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
10. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2022. PMID: 36375046.
11. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
12. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
13. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
14. Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping J, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine 56:101779, 2023. e-Pub 2022. PMID: 36618900.
15. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
16. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. PMID: 36384092.
17. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
18. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
19. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
20. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2021. PMID: 34435552.
21. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2021. PMID: 34797699.
22. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. e-Pub 2022. PMID: 35074072.
23. Handley G, Khawaja F, Kondapi DS, Lee HJ, Kaufman GP, Neelapu SS, Fayad LE, Tummala S, Chi L, Strati P, Mulanovich VE. Human Herpesvirus-6 Myelitis after Chimeric Antigen Receptor T-cell Therapy. Int J Infect Dis 112:327-329, 2021. e-Pub 2021. PMID: 34600133.
24. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw 19(11):1218-1230, 2021. PMID: 34781267.
25. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
26. Minamimoto R, Fayad L, Vose J, Meza J, Advani R, Hankins J, Mottaghy F, Macapinlac H, Heinzel A, Juweid ME, Quon A. 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. Eur J Nucl Med Mol Imaging 48(9):2883-2893, 2021. e-Pub 2021. PMID: 33909086.
27. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
28. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
29. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
30. Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 21(5):309-317.e3, 2021. e-Pub 2020. PMID: 33632668.
31. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2020. PMID: 32932518.
32. Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192(3):667-671, 2021. e-Pub 2020. PMID: 33238033.
33. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):278-281, 2021. e-Pub 2020. PMID: 32636464.
34. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32628087.
35. Furqan F, Watson G, Samaniego F, Fayad LE, Rashmi Kanagal-Shamanna , Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32650677.
36. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
37. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. e-Pub 2020. PMID: 33020644.
38. Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol. e-Pub 2020. PMID: 33065767.
39. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
40. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
41. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
42. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. PMID: 32589728.
43. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
44. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
45. van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol 7(3):e209-e217, 2020. e-Pub 2020. PMID: 32027862.
46. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
47. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2019. PMID: 31533521.
48. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
49. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma 60(13):1-8, 2019. e-Pub 2019. PMID: 31234671.
50. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk 19(11):709-714, 2019. e-Pub 2019. PMID: 31446000.
51. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma 60(10):1-9, 2019. e-Pub 2019. PMID: 30942648.
52. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
53. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
54. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
55. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
56. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw 17(6):650-661, 2019. PMID: 31200358.
57. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Ann Hematol 98(5):1169-1176, 2019. e-Pub 2019. PMID: 30617643.
58. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 185(4):670-678, 2019. e-Pub 2019. PMID: 30820940.
59. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
60. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
61. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol 185(2):334-338, 2019. e-Pub 2018. PMID: 29978452.
62. Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma 60(4):1-10, 2019. e-Pub 2018. PMID: 30277102.
63. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk 19(4):244-250, 2019. e-Pub 2019. PMID: 30686775.
64. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study. Haematologica 104(2):e65-e67, 2019. e-Pub 2018. PMID: 30190343.
65. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2018. PMID: 30360985.
66. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma 59(12):1-8, 2018. e-Pub 2018. PMID: 29697005.
67. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
68. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer 6(1):119, 2018. e-Pub 2018. PMID: 30446007.
69. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
70. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
71. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
72. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182(4):583-586, 2018. e-Pub 2017. PMID: 28677896.
73. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. e-Pub 2018. PMID: 30124609.
74. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
75. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
76. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
77. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9(48):28897-28902, 2018. e-Pub 2018. PMID: 29988979.
78. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
79. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
80. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
81. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):863-870, 2018. e-Pub 2017. PMID: 28792260.
82. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
83. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
84. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179(5):851-854, 2017. e-Pub 2016. PMID: 27502933.
85. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
86. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
87. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. Br J Haematol 179(3):488-496, 2017. e-Pub 2017. PMID: 28832956.
88. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
89. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
90. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
91. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Netw 15(3):293-311, 2017. PMID: 28275031.
92. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol 175(3):531-533, 2016. e-Pub 2015. PMID: 26683805.
93. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
94. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
95. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw 14(9):1067-79, 2016. PMID: 27587620.
96. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthal Plast Reconstr Surg. e-Pub 2016. PMID: 27636243.
97. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. PMID: 27227654.
98. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, Fayad LE, Fisch MJ, Yeh ET. The Utility of Point of Care Biomarkers to Detect Cardiotoxicity during Anthracycline Chemotherapy: A Feasibility Study. J Card Fail 22(6):433-8, 2016. e-Pub 2016. PMID: 27079675.
99. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. e-Pub 2016. PMID: 27091808.
100. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
101. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw 14(2):196-231, 2016. PMID: 26850490.
102. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology:150689. e-Pub 2016. PMID: 26854705.
103. Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, Lin BK, Fayad LE. An open-label, randomized, phase 2 Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- or high-riskdiffuse large B-cell lymphoma. Leuk Lymphoma 57(1):1-11, 2016. e-Pub 2015. PMID: 25956042.
104. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2015. PMID: 26648336.
105. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 2016. PMID: 26802151.
106. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis -TAFRO syndrome. Am J Hematol 90(11):1091-2, 2015. e-Pub 2015. PMID: 25808231.
107. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
108. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
109. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 2015. e-Pub 2015. PMID: 26213141.
110. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 7(314):314ra185, 2015. PMID: 26582900.
111. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. e-Pub 2015. PMID: 26640039.
112. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma:1-8. e-Pub 2015. PMID: 25804933.
113. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 6(30):30408-19, 2015. e-Pub 2015. PMID: 26327301.
114. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol 33(30):3467-74, 2015. e-Pub 2015. PMID: 26282650.
115. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 2015. e-Pub 2015. PMID: 25818067.
116. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
117. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
118. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 92(1):122-9, 2015. e-Pub 2015. PMID: 25754633.
119. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. PMID: 25863759.
120. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. PMID: 25863764.
121. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2014. PMID: 25445468.
122. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw 13(3):326-62, 2015. PMID: 25736010.
123. Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma:1-10. e-Pub 2015. PMID: 25651427.
124. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
125. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
126. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
127. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 4.2014. J Natl Compr Canc Netw 12(9):1282-303, 2014. PMID: 25190696.
128. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 2014. e-Pub 2014. PMID: 24721592.
129. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 12(6):916-46, 2014. PMID: 24925202.
130. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165(1):146-7, 2014. e-Pub 2013. PMID: 24329994.
131. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
132. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. J Clin Oncol 32(8):798-808, 2014. e-Pub 2013. PMID: 24344220.
133. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. J Clin Oncol 32(2):114-20, 2014. e-Pub 2013. PMID: 24323027.
134. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 54(12):2631-8, 2013. e-Pub 2013. PMID: 23488661.
135. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
136. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clin Cancer Res 19(24):6882-90, 2013. e-Pub 2013. PMID: 24097867.
137. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5(+) Diffuse Large B cell Lymphoma (DLBCL). Am J Hematol 88(9):798-802, 2013. e-Pub 2013. PMID: 23695956.
138. Romaguera JE, Fayad LE, Wang M, McLaughlin PW, Neelapu S. Nuclear Translocation of B-cell specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLOS one, 2013. PMID: 23936317.
139. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicophathologic study of 10 cases. Am J Surg Pathol 37(8):1290-7, 2013. e-Pub 2013. PMID: 23774171.
140. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 2013. e-Pub 2013. PMID: 23590726.
141. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera JE, Samaneigo F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (marqibo) substituted for non-liposomal vincristine in CHOP with or without rituximab for patients with untreated aggressive non-hodgkin's lymphomas. Br J Haemaol, 2013. e-Pub 2013. PMID: 238027358.
142. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, Van Rhee F. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. Clin Cancer Res. e-Pub 2013. PMID: 23659971.
143. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. e-Pub 2013. PMID: 23692856.
144. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, McLaughlin P, Oki Y, Pro B, Rodriguez MA, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K, Desai M, Badillo M, Bejarano M, Sun L, Young KH, Samuel C, Hartig K, Chen W, Byrne C, Bell N, Takashida K, Champlin R, Kwak L, Fayad L. Lenalidomide in combination with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma, follicular grade 3 lymphoma, and transformed B cell lymphoma: a phase 2 clinical trial. Leukemia, 2013. e-Pub 2013. PMID: 23545991.
145. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2012. PMID: 23276888.
146. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad LE. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 2013. e-Pub 2013. PMID: 23545991.
147. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphomas, Version 1.2013. J Natl Compr Canc Netw 11(3):257-273, 2013. PMID: 23486452.
148. Fayad LE, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. J Clin Oncol. e-Pub 2013. PMID: 23295790.
149. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk. e-Pub 2012. PMID: 23137719.
150. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159(2):243-6, 2012. e-Pub 2012. PMID: 22924544.
151. Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, Jorgensen JL, de Peralta-Venturina M, Mustafa EB, Young KH, You MJ, Fayad LE, Blenc AM, Miranda RN. Anaplastic Large Cell Lymphoma Associated With Breast Implants: A Report of 13 Cases. Am J Surg Pathol 36(7):1000-1008, 2012. PMID: 22613996.
152. Wang M, Fayad LE, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak LW, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera JE. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology 13(7):716-723, 2012.
153. Weng J, Rawal S, Park HJ, Sharma R, Fayad LE, Fanale M, Romaguera JE, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood, 2012.
154. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
155. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma 53(5):990-2, 2012. e-Pub 2012. PMID: 21988665.
156. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Dirienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A, on behalf of the 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119(16):3698-3704, 2012. e-Pub 2012. PMID: 22389254.
157. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 2012. e-Pub 2012. PMID: 22357140.
158. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118(6):1566-73, 2012. e-Pub 2011. PMID: 21882178.
159. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 2012. e-Pub 2012. PMID: 22294726.
160. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 2012. PMID: 22383790.
161. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-18.e2, 2012. e-Pub 2011. PMID: 22024108.
162. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. Leuk Lymphoma 53(1):50-6, 2012. e-Pub 2011. PMID: 21895545.
163. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25(1):145-56, 2012. e-Pub 2011. PMID: 22002575.
164. Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 Study With a Dose-Expansion Cohort. Cancer 117(22):5067-73, 2011. e-Pub 2011. PMID: 21681734.
165. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. e-Pub 2011. PMID: 21844567.
166. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez MA, Hagemeister FB, Buesco-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah JJ, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann of Oncol 10:1093, 2011.
167. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 2011. e-Pub 2011. PMID: 21517809.
168. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw 9(5):484-560, 2011. PMID: 21550968.
169. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?. Curr Hematol Malig Rep 6(1):58-66, 2011. PMID: 21191675.
170. Greaves WO, Bueso-Ramos C, Fayad L. Classical Hodgkin's Lymphoma Associated With Langerhans Cell Histiocytosis: Multiagent Chemotherapy Resulted in Histologic Resolution of Both the Classical Hodgkin's Lymphoma and Langerhans Cell Proliferation Components. J Clin Oncol 29(4):e76-8, 2011. e-Pub 2010. PMID: 21041711.
171. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 2010. e-Pub 2010. PMID: 20851072.
172. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 2010. e-Pub 2010. PMID: 20735402.
173. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-41, 2010. PMID: 20920696.
174. Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS. Marginal zone lymphomas: factors that affect the final outcome. Cancer 116(18):4291-8, 2010. e-Pub 2010. PMID: 20549822.
175. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1649-57, 2010. PMID: 20807093.
176. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170-6, 2010. e-Pub 2010. PMID: 20713859.
177. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. J Clin Oncol 28(23):3701-8, 2010. e-Pub 2010. PMID: 20625121.
178. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. e-Pub 2010. PMID: 20528872.
179. Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med 51(5):824-5, 2010. PMID: 20439512.
180. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28(12):2085-93, 2010. e-Pub 2010. PMID: 20308665.
181. Tomas JF, Dang J, Pro B, Rodriguez MA, McLaughlin P, Romaguera JE, Younes A, Hagemeister F, Cabanillas F, Podoloff D, Fayad LE. El tamizaje con galio despues del segundo y cuarto ciclos de quimioterapia es predictor de linfomas no Hodgkin. Revista de Hematol 11:5-14, 2010.
182. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 8(3):288-334, 2010. PMID: 20202462.
183. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. J Clin Oncol 27(32):5425-30, 2009. e-Pub 2009. PMID: 19805674.
184. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. Mod Pathol 22(10):1312-20, 2009. e-Pub 2009. PMID: 19593328.
185. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 4(4):218-24, 2009. PMID: 20425411.
186. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 27(20):3346-53, 2009. e-Pub 2009. PMID: 19451441.
187. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 2009. e-Pub 2009. PMID: 19150940.
188. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 2008. PMID: 18973182.
189. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112(6):2583; author reply 2583-4, 2008. PMID: 18779406.
190. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3):355-60. e-Pub 2008. PMID: 18764869.
191. Zelenter AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacase AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 6(4):356-421, 2008. PMID: 18433606.
192. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6. e-Pub 2008. PMID: 18411419.
193. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 112(4):553-559, 2008. e-Pub 2007. PMID: 18083690.
194. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Veno NT; Hosing C; Khouri IF; Couril D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 93(2):257-264, 2008. e-Pub 2008. PMID: 18223284.
195. Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-836, 2008. PMID: 18085611.
196. Friedberg JW, Williams ME, van der Jagt RH, Forero-Torres A, LaCasce AS, Fayad LE, Bessudo A, Camacho ES, Oliver JW, Chen L, Cohen P, Cheson BD, Robinson KS. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204-210, 2008. PMID: 18182663.
197. Provencio M, Fayad LE. [High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma]. Med Clin (Barc) 130(2):60-5, 2008. PMID: 18221676.
198. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2:S57-62, 2007. PMID: 18284717.
199. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B.. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. Am J Hematol 82(8)(8):725-8, 2007. PMID: 17373675.
200. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B.. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4)(4):502-505, 2007. e-Pub 2007. PMID: 17608763.
201. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L.. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma. Cancer 109(12):2481-9, 2007.
202. Iwuanyanwu E, Medeiros J, Romaguera JE, Fayad L.. Mantle Cell Lymphoma with a Rare Involvement of the Testicle. Leuk Lymphoma 48(6)(6):1242-3, 2007. PMID: 17577795.
203. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 2007. PMID: 17497648.
204. Fayad L, Hagemeister F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. Leuk Lymphoma 48(4):657-8, 2007. PMID: 17454622.
205. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109(5):2174-82, 2007. e-Pub 2006. PMID: 17090655.
206. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2007. PMID: 17233846.
207. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 48(2):374-80, 2007. PMID: 17325899.
208. Hagemeister FB, Fayad L.. The FLIPI and the R-FLIPI: Are we finally ready to use them in Clinical Trials?. Am J Hem-Onc 6(6):364-368, 2007.
209. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastaba PK, Younes A. Experience with heat schock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 2007.
210. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. e-Pub 2006. PMID: 17054068.
211. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 2006. e-Pub 2006. PMID: 17008093.
212. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 2006. PMID: 16902984.
213. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 7(6):733-48, 2006. PMID: 16556089.
214. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 2006. PMID: 16575009.
215. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 2006. PMID: 16396772.
216. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(3):258-310, 2006. PMID: 16507273.
217. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107(4):1731-2, 2006. PMID: 16461762.
218. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 2005. e-Pub 2005. PMID: 16145068.
219. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 2005. PMID: 15806128.
220. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 2005. PMID: 15800314.
221. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2005. e-Pub 2004. PMID: 15613697.
222. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. e-Pub 2004. PMID: 15353540.
223. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Non-ablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 2003. PMID: 14645431.
224. Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, Wilder RB, Cabanillas F, Cox JD. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 57(3):748-54, 2003. PMID: 14529780.
225. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, 2003. PMID: 12883733.
226. Goy A, Ramdas L, Remache YK, Gu J, Fayad L, Hayes KJ, Coombes KR, Barkoh BA, Katz R, Ford R, Cabanillas F, Gilles F. Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. Lab Invest 83(6):913-6, 2003. PMID: 12808126.
227. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 2003. PMID: 12702528.
228. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2003. PMID: 12548600.
229. Younes A, Fayad L, Pro B, McLaughlin P, Hagemeister F, Mansfield P, Clayman G, Medeiros LJ, Manning J, Lewis J, Srivastava P. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. Blood 102(11):898a, 2003.
230. Fayad L. Durable Local responses with Subtherapeutic doses of concurrent Radiation and Gemcitabine in a patient with refractory Hodgkin’s disease: Review of Halepota et al case. Clin Adv in Hematol & Oncol 1(7):416, 2003.
231. Fayad L, Pro B, Romaguera JE. Mantle cell lymphoma: A review. Hematología, Citocinas, Y Terapia Celular 2:100-112, 2003.
232. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256-63, 2001. PMID: 11133769.
233. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Economics Impact on Use of Blood Transfusions and Eryhropoietin-Stimulating Agents in Patients with Diffuse Large B-Cell Lymphoma. Cancer.
234. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad LE, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, Cyclophosphamide, and Rituximab (PCR) for Previously Untreated Advanced Stage, Low-grade B-cell Lymphomas.
235. Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Oczan M, Fayad LE, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma.
236. Dabaja B, Milgrom S, Smith G, Romaguera JE, Turturro F, Fowler N, Fayad LE, Nastoupil L, Westin J, Neelapu S, Rodriguez MA, Fanale M, Hagemeister FB, Lee HJ, Oki Y, Wang B, Samaniego F, Chi L. Ultra‐Low‐Dose Radiation Therapy for Definitive Management of Ocular Adnexal B‐Cell Lymphoma. Head & Neck.
237. Fanale MA, Cheah C, Rich A, Medeiros LJ, Lai CM, Oki Y, ROmaguera JE, Fayad LE, Hagemesiter F, Samaniego F, Rodriguez MA, Neelapu S, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz S, Younes A. Potential Improvement of Clinical Outcomes for Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated With R-CHOP.
238. Milgrom SA, Pinnix CC, Akhtari M, Oki Y, Smith GL, Reddy JP, Gunther JR, Mawlawi O, Garg N, Rohren E, Chuang H, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Yehia A, Fanale M, Dabaja BS. Early-Stage Hodgkin Lymphoma Outcomes After Combined Modality Therapy According to the Deauville 5-Point Score. Annals of Oncol.

Other Articles

1. Provencio M; Fayad LE High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma. Medicina clinica 130(2):60-65, 2008.

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. PMID: 24332512.

Abstracts

1. Dai Chihara, Nathan H. Fowler, Yasuhiro Oki, Michelle A. Fanale, Loretta Nastoupil, Jason R. Westin, Luis E. Fayad, Sattva S. Neelapu and Chan Yoon Cheah. Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Blood 130:4137, 2017.
2. Preetesh Jain, Rashmi Kanagal-Shamanna, Ahmad Ghorab, Loretta Nastoupil, Luis E. Fayad, Jeffrey Medeiros, Shimin Hu, Sattva S. Neelapu, Jason R. Westin, Yasuhiro Oki, Michael Wang and Nathan H. Fowler. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. Blood 130:2852, 2017.
3. Issa F. Khouri, Hui Gao, Denái R. Milton, Martin Korbling, Celina Ledesma, Luis E. Fayad, Elias J. Jabbour, Alison M. Gulbis and James M. Reuben. Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL). Blood 130:1925, 2017.
4. Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta Nastoupil, Sattva S. Neelapu, Luis E. Fayad, Nathan H. Fowler and Chan Yoon Cheah. Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement. Blood 130:1569, 2017.
5. Paolo Strati, Yasuhiro Oki, Luis E. Fayad, Loretta Nastoupil, Nathan H. Fowler, F. B. Hagemeister, Larry W Kwak, Hun Ju Lee, Michael Wang, Jason R. Westin, Charnelle Ruben, Emily Wesson and Michelle A. Fanale. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood 130:4074, 2017.
6. Issa F. Khouri, Elias J. Jabbour, Celina Ledesma, Martin Korbling, Amin M. Alousi, Paolo Anderlini, Betul Oran, Stefan O. Ciurea, Luis E. Fayad, Roland L. Bassett Jr. and Alison M. Gulbis. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results. Blood 130:2036, 2017.
7. Melody R Becnel, Loretta Nastoupil, R. Eric Davis, F. B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Michael Wang, Yasuhiro Oki, Linda Claret, Sheryl G Forbes, Lei Feng, Felipe Samaniego, Sattva S. Neelapu and Nathan Fowler. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood 130:4040, 2017.
8. Jason R. Westin, Yasuhiro Oki, Loretta Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, F. B. Hagemeister, Maria Alma Rodriguez, Hun Ju Lee, Ken H. Young, Timothy J. McDonnell, Richard J. Ford and R. Eric Davis. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. Blood 130:189, 2017.
9. Khashab T, Niaz O, Hagemeister FB, Romaguera JE , Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad LE, Younes A, Feng L, Berkova Z, Jain N, Sehgal L, Vega F, Kwak LW, Samaniego F. Ten-year follow-up of Pentostatin Combined with Cyclophosphamide, and Rituximab in untreated indolent B-Cell Lymphoma. J Clin Oncol ASCO 2017, 2017.
10. Hu B, Loghavi S, Fayad LE, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. J Clin Oncol ASCO 2017, 2017.
11. Budde LE, Halwani A, Yasenchak CA, Farber CM, Burke JM, Fayad LE, Holkova B, Knapp M, Kolibaba KS, Advani RH, Ansell SM, Patel-Donnelly D, Yimer HA, Smith SE, Yair Levy M, Seetharam M, Belada D, Brooks D, Kingsley EC, Klein LM, Wagner-Johnston N, Ruffner K, Bartlett NL. Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood (2016 ASH Annual Meeting) 128(26):104, 2016.
12. Sathyanarayanan V, Oki Y, Issa AK,Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez AM, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy—the University of Texas MD Anderson Experience. Blood (2016 ASH Annual Meeting) 128(26):106, 2016.
13. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W*, Oriabure O*, Huang SY, Li S, Zhang L, Badillo M, Hartig KH*, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood (2016 ASH Annual Meeting) 128(26):147, 2016.
14. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood (2016 ASH Annual Meeting) 128(26):1833, 2016.
15. Jain P, Kanagal-Shamanna R, San Lucas F, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JE, Medeiros LJ, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). Blood (2016 ASH Annual Meeting) 128(26):2975, 2016.
16. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(26):4153, 2016.
17. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (2016 ASH Annual Meeting) 128(26):4208, 2016.
18. Crump M, Leppä S, Fayad LE, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SY, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphom. J Clin Oncol 34:2484-2492, 2016.
19. Fowler N, Pinto R, Cheah CY, Neelapu S, Turturro F, Hagemeister F, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood (ASH Annual Meeting Abstracts) 126(23):2742, 2015.
20. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Lourdes Dela Rosa M, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin R, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood (ASH Annual Meeting Abstracts) 126(23):3969, 2015.
21. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister F, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (ASH Annual Meeting Abstracts) 126(23):3984, 2015.
22. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister F, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 126(23):2738, 2015.
23. Chihara D, Oki Y, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horowitz SB, Feng L, Garg N, Ahmed S, Khouri IF, Hosing CM, Romaguera JE, Fowler N, Fanale MA. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood (ASH Annual Meeting Abstracts) 126(23):3987, 2015.
24. Fanale MA, Wang A, Ma W, Oki Y, Hagemeister FB, Fayad LE, Fowler N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 126(23):2705, 2015.
25. Ahmed MA, Oki Y, Noorani M, Nastoupil L, Fayad LE, Hagemeister FB, Rodriguez A, Davis RE, Westin JR. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood (ASH Annual Meeting Abstracts) 126(23):3965, 2015.
26. Yasenchak CA, Halwani A, Advani R, Ansell S, Budde LE, Burke JM, Farber CM, Holkova B, Fayad LE, Kolibaba KS, Knapp M, Li M, Manley TJ, Patel-Donnelly D, Seetharam M, Yimer HA, Bartlett NA. Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 126(23):814, 2015.
27. Khouri I, Sui D, Turturro F, Erwin WD, Bassett Jr. RJ, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Oran B, Olson A, Popat, Patel KK, Qazilbash M, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros LJ, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood (ASH Annual Meeting Abstracts) 126(23):3192, 2015.
28. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts) 126(23):1502, 2015.
29. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol:3467-3474, 2015.
30. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad LE, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol ASCO MEETING(8528), 2014.
31. Jain P, Patel K, Bueso-Ramos CE, Romaguera JE, Fayad LE, Kwak LW, Fowler N. Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center. J Clin Oncol ASCO MEETING(8596), 2014.
32. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford JA, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Gine E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol ASCO MEETING(8529), 2014.
33. Ahmed MA, Barac R, Medeiros LJ, Ma L, Fayad LE, Romaguera JE, Oki Y, Rodriguez MA, Pinnix C, Kwak LW, Hagemeister FB, Davis RE, Westin JR. Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. J Clin Oncol ASCO MEETING(8564), 2014.
34. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Velez Bravo VM, Hong DS, Westin JR, Nunez C, Fayad LE, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol ASCO MEETING(8508), 2014.
35. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad LE, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh R, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 122(21):499-506, 2013.
36. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 122(21):3028, 2013.
37. Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):3033, 2013.
38. Kantarjian HM, Cortes JE, Jabbour EJ, Faderl SH, Wierda WG, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Ravandi R, O'Brien S, Thomas D. Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. Blood (ASH Annual Meeting Abstracts) 122(21):3917, 2013.
39. Neelapu SS, Fanale MA, Kwak LW, Fayad LE, Rodriguez AM, Wallace M, Carlton V, Kong K, Faham M, Younes A. Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay. Blood (ASH Annual Meeting Abstracts) 122(21):627, 2013.
40. Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 122(21):5122, 2013.
41. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood (ASH Annual Meeting Abstracts) 122(21):3048, 2013.
42. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(21):1776, 2013.
43. Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease. Blood (ASH Annual Meeting Abstracts) 122(21):1806, 2013.
44. Leppä S, Fayad LE, Lee JJ, Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin RM, Mackensen A, Offner F, Pinter-Brown, Smith SO, Tobinai K, Yeh SP, Zhu J, Hahka-Kemppinen M, Thornton D, Shi P, Lin, Kahl BS, Schmitz N, Savage KJ, Habermann TM. A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. Blood (ASH Annual Meeting Abstracts) 122(21):371, 2013.
45. Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood (ASH Annual Meeting Abstracts) 122(21):3350, 2013.
46. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, KwohTJ, MacLeod AR, Norris D, Baldwin R, Hung G, Monia BP, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol, 2013.
47. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad LE. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(3707), 2012.
48. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad LE, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood (ASH Annual Meeting Abstracts) 120(2406), 2012.
49. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 120(793), 2012.
50. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 120(1529), 2012.
51. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood (ASH Annual Meeting Abstracts) 120(3670), 2012.
52. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte L, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstracts) 120(901), 2012.
53. Zhang K, Pham LV, Tamayo AT, Lee J, Bryant J, Younes A, Fayad LE, Yang DJ, Ford RJ. Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 120(1305), 2012.
54. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chung Chan W, Vose J, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 120(2709), 2012.
55. Pham LV, Rollo A, Tamayo AT, Lee J, Zuo Z, Sun L, Zhang L, Ou Z, Fayad LE, Wang M, Ford RJ. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 120(2717), 2012.
56. Khouri IF, Rima SM, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bash Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 120(4157), 2012.
57. Jabbour E, O'Brien SM, Thomas D, Jorgensen JL, Kebriaei P, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang S, Champlin RE, Advani AS, Kantarjian H. Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). J Clin Oncol 30(6501), 2012.
58. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. J Clin Oncol 30(8067), 2012.
59. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA), 2012.
60. Samaneigo F, Wise J, Fayad LE, Fanale M, Hagemeister F, Sevaraj V, Goldenberg D, Kwak LK, Berkova Z. Anti-CD74 antibody hLL1 effects including bone marrow homing in lymphoma and chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 118(1796), 2011.
61. Younes A, Copeland A, Fanale M, Fayad LE, Romaguera JE, Kwak LW, Neelapu S, Hagemeister F, Pro B, de Castro Faria S, Ji Y, Berry D, Buglio D, Medeiros J. Safety and efficacy of the novel combination of panobinostat (LBH589) and everloimus (RAD001) in relapsed/refractory hodgkin and non-hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 118(3718), 2011.
62. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad LE, Liao Q, Edvardsen K, Lisby K, Moskowitz CH. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). Blood (ASH Annual Meeting Abstracts) 118(957), 2011.
63. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad LE, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Qi M, Cornfeld MJ, van Rhee F. Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. Blood (ASH Annual Meeting Abstracts) 118(3959), 2011.
64. O'Brien S, Thomas DA, Ohanian M, Jorgensen JL, Kebriaei P, Jabbour E, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang SA, Champlin R, Advani AS, Kantarjian HM. Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL). Blood (ASH Annual Meeting Abstracts) 118(875), 2011.
65. Bollard CM, Gottschalk S, Sheehan AM, Carrum G, Liu H, Pro B, Fayad LE, Younes A, Mims M, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood (ASH Annual Meeting Abstracts) 118(956), 2011.
66. Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang L, Fayad LE, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. Blood (ASH Annual Meeting Abstracts) 118(3650), 2011.
67. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera JE, Fanale MA, Fayad LE, Fowler NH, Huen A, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Younes A, Kwak LW. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood (ASH Annual Meeting Abstracts) 118(1613), 2011.
68. Dabaja BS, Phan J, Medeiros JL, Hagemeister FB, Chuang H, Fayad LE, Shihadeh F, Allen P, Wogan C, Rodriguez MA. Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(2695), 2011.
69. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli S, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood (ASH Annual Meeting Abstracts) 118(2698), 2011.
70. Pham LV, Tamayo AT, Li C, Lee J, Fayad LE, Ford RJ. Chemo-Resistance in Diffuse Large Cell Lymphoma: Novel Drug Combinations Targeting NFAT/NF-Kb Growth/Survival/Chemo-Resistance Signaling Pathways in Validated Novel Experimental Systems. Blood (ASH Annual Meeting Abstracts) 118(1428), 2011.
71. Younes A, Kim S, Romaguera JE, Copeland A, de Castro Farial S, Kwak LW, Fayad LE, Hagemeister F, Fanale M, Lambert LM, Morariu-Zamfir R, Gordon L. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory b-cell lymphoma. J Clin Oncol, 2011.
72. Samaniego F, Hagemeister F, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Lacerte L, Fowler N. High response rates with lenalidomide plus rituximab for untreated indolent b cell non-hodgkins lymphoma, including those meeting GELF criteria. J Clin Oncol 29(15):8030, 2011.
73. Fanale M, Vigil K, Lai CM, Feng L, Dong W, Younes A, Romaguera JE, Fayad LE, Hagemeister FB, Mulanovich V. Outcomes of HIV positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era. J Clin Oncol 29(15):2011, 2011.
74. Rodriguez MA, Durand JB, Astrow AB, Bury MJ, Fanale M, Hagemeister FB, Huang X, McLauglin P, Neelapu SS, Pro B, Kwak LW, Fayad LE, Romaguera JE, Younes A, Fisch M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients >60 years old with untreated diffuse large b cell lymphoma (DLBCL). J Clin Oncol 29(15):8053, 2011.
75. Dabaja BS, Phan J, Medeiros LJ, Chuang H, Fayad LE, Hagemeister F, Shihadeh FDA, Allen P, Rodriguez MA. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large b-cell lymphoma. J Clin Oncol 29(15):2011, 2011.
76. Hainsworth JD, Arrowsmith E, McCleod M, Fayad LE, Hamid O, Davis L, Lin BK. Randomized phase II study of r-CHOP plus enzastaurin versus r-Chop in the first-line treatment of patients with intermediate and high-risk diffuse large b-cell lymphoma (DLBCL) - preliminary analysis. J Clin Oncol 29(15):8016, 2011.
77. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 16th European Hematology Conference, London, England 22(4):218, 2011.
78. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2011.
79. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
80. Younes A, Copeland A, Fanale MA, Hagemeister F, Fayad LE, Pro B, Faria SC, Ji Y, Medeiros JL, Berry DA, Buglio D. Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. American Society of Hematology (Blood) 116(3964), 2010.
81. Fanale MA, Lai CM, McLaughlin P, Romaguera JE, Fayad LE, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak LW, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. American Society of Hematology (Blood) 116(2812), 2010.
82. Raj SV, Hagemeister F, Fayad LE, Zhou X, ORoark SS, Ames K, Rodriguez MA, Fanale MA, Pro B, Johnson MM, McLaughlin P, Bueso-Ramos CE, Younes A, Kwak LW, Romaguera JE. Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study. American Society of Hematology (Blood) 116(21):1544, 2010.
83. Thomas DA, Faderl S, O'Brien S, Wierda WG, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau S, Fayad LE, Romaguera JE, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. American Society of Hematology (Blood) 116(22):2831, 2010.
84. Hamlin PA, Rodriguez MA, Noy A, Portlock CS, Straus D, McLaughlin P, Pro B, Fayad L, Hagemeister FB, Wegner B, Dumitrescu O, Pandit Tasker N, Moskowitz CH, Zelenetz AD. Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (Blood) 116(21):1793, 2010.
85. Al-Ameri AM, Badoux X, Ferrajoli A, Wierda W, Fayad LE, Estrov Z, Bickel S, Keating MJ, O'Brien S. Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. American Society of Hematology (Blood) 116(21):4488, 2010.
86. Okoroji GJ, de Padua Silva G, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad LE, Samaniego F, Fowler N, Champlin R, Hagemeister FB, Khouri I. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. American Society of Hematology (Blood) 3510 116(21):3510, 2010.
87. Fowler M, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu A, Fayad LE, Orlowski R, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol (Meeting Abstracts) 28:8036, 2010.
88. Pro B, Perini G, Feng L, Romaguera J, Rodriguez MA, McLaughlin P, Hagemeister F, Fayad L, Kadia TM. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. J Clin Oncol (Meeting Abstracts) 28:8048, 2010.
89. Pozadzides JV, Perini G, Hess M, Romaguera JE, Hagemeister FB, McLaughlin P, Fayad LE, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. J Clin Oncol (Meeting Abstracts) 28:850, 2010.
90. Perini G, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister F, Samaniego F, Kwak LW, Fayad LE. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. J Clin Oncol (Meeting Abstracts) 28:8072, 2010.
91. Manoukian G, Hagemeister F, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). J Clin Oncol (Meeting Abstracts) 28:8078, 2010.
92. Hagenbeek A, Fayad LE, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, Bang B, Russell C, Czuczman MS. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:935, 2009.
93. Dang NH, Smith MR, Offner F, Verhoef G, Johnson P, Rohatiner AZ, Kaufman JL, Gine E, Coiffier B, Czuczman MS, Foran J, Durrant S, Hua S, Vandendries ER, Fayad LE. Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:584, 2009.
94. Thomas DA, Faderl S, O'Brien S, Wierda WG, Ravandi F, Garcia-Manero G, Verstovsek S, Kornblau S, Fayad LE, Cortes J, Kantarjian HM. Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update. Blood (ASH Annual Meeting Abstracts) 114:4099, 2009.
95. Copeland AR, Cao Y, Fanale M, Fayad LE, McLaughlin P, Pro B, Hagemeister F, Romaguera JE, Samaniego F, Rodriguez MA, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data. Blood (ASH Annual Meeting Abstracts) 114:1680, 2009.
96. Fowler N, McLaughlin P, Hagemeister FB, Kwak L, Fanale M, Neelapu S, Fayad LE, Pro B, Sergent C, White S, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:1714, 2009.
97. Jones D, Windham J, Stewart B, Fayad LE, Rodriguez MA, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. Blood (ASH Annual Meeting Abstracts) 114:968, 2009.
98. Wang M, Fayad LE, Hagemeister FB, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis JB, Cabanillas F, Kwak L, Romaguera JE. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:2719, 2009.
99. Westin JR, Thompson MA, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah J, Hagemeister FB. Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114:3922, 2009.
100. Vadhan-Raj S, Fayad LE, Fanale M, Pro B, Rodriguez MA, Hagemeister F, Ames K, Bueso-Ramos CE, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera JE. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood (ASH Annual Meeting Abstracts) 114:105, 2009.
101. Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett, Jr. R, Amin A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad LE, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood (ASH Annual Meeting Abstracts) 114:868, 2009.
102. Younes A, Copeland A, Romaguera JE, Fayad LE, Fanale M, de Castro Faria S, Medeiros LJ, Percy Ivy S. Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:3744, 2009.
103. Younes A, Gordon L, Kim S, Romaguera JE, Copeland AR, de Castro Farial S, Kwak L, Fayad LE, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114:585, 2009.
104. Westin JR, Thompson MW, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah JJ, Hagemeister FB. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. American Society of Hematology (Blood) 114(22):3922, 2009.
105. Fowler N, McLaughlin P, Kwak LW, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 27(15S):445, 2009.
106. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT pathway activation in primary mediastinal large B-cell lymphoma produces distinct patterns of cytokine pathway response and predicted sensitivity to small molecule inhibitors. Blood, 2009.
107. Fayad LE, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani Anjali, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and clinical activity of the anit-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymhoma: preliminary report of a phase 1/2 study. Blood 112(266), 2008.
108. Fanale MA, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. A phase I study of bortezomib in combination with ice (bice) in patient with relapsed/refractory classical hodgkin lymphoma. Blood 112(3048), 2008.
109. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trail of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 112(3051), 2008.
110. Wang M, Zhang L, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(3058), 2008.
111. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Wierda WG, Ravandi F, Rodriguez MA, Fayad LE, O'Brien S. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for burkitt (BL) or burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (ALL). Blood 112(1929), 2008.
112. Mazloom A, Reed VK, Cabanillas F, Fayad LE, Pro B, Iyengar P, McLaughlin P, Urbauer DL, Dabaja BS. Marginal zone lymphoma: factors that affect the final outcome, a study of 275 patients. Blood 112(3764), 2008.
113. Cataldo VD, Thompson MA, Toth BB, Sanjorjo P, Bekele BN, Jimenez C, Murphy WA, Huen AO, Arbuckle RB, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin PW, Neelapu SS, Pro B, Rodriguez AM, Shah J, Hagemeister FB. Bone loss in patients with previously untreated lymphoma: the effect of periodontal disease on the use of zoledronic acid. Blood 112(5297), 2008.
114. Romaguera JE, Fayad LE, Rodriguez AM, Hagemeister FB, Pro B, McLaughlin PW, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with r-methotrexate/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood 112(833), 2008.
115. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez MA, Fayad LE, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. Blood 112(835), 2008.
116. Van Rhee F, Fayad LE, Voorhees P, Furman RR, Borghaei H, Lonial S, Sokol L, Crawford J, Cornfeld M, Qi M, Herring J, Qin X, Kurzrock R. CNTO 328, a monoclonal antibody to interleukin-6, is active as a study agent in Castleman's disease: preliminary results of a phase I study. Blood 112(1008), 2008.
117. Kurzrock R, Fayad LE, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F,. A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-hodgkin's lymphoma, multiple myeloma, or castleman's disease. Blood 112(1009), 2008.
118. Garg RJ, Wierda W, Fayad LE, Estrov Z, Bickel SM, O'Brien, S. Phase II study of dasatinib in patients with relapsed CLL. Blood 112(4197), 2008.
119. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korblin M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogenic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 2008.
120. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Colffier B, Morchhauser F. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. J Clin Oncol 26(15S):142s, 2008.
121. Cultrera JL, Nunez RF, Romaguera JE, Hagemeister FB, Rodriguez MA, Fayad LE, Pro B. Early Fluro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). J Clin Oncol 26(15S):463s, 2008.
122. Shah N, Cabanillas F, Feng L, McIntyre B, McLaughlin P, Rodriguez MA, Romaguera JE, Younes A, Hagemeister FB, Kwak L, Fayad LE. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. J Clin Oncol 26(15S):475s, 2008.
123. Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, fENG l, Younes A. Long-term follow-up of pacitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(15S):478s, 2008.
124. Rodriguez MA, Fanale M, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Durand J. Acitivity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. J Clin Oncol 26(15S):725s, 2008.
125. Zhou X, Huen A, Teegala S, Ji S, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. J Clin Oncol 26(15S):726s, 2008.
126. Hamlin PA, Moskowitz CH, Wegner B, Noy A, Gerecitano J, Palomba ML, Portlock C, Straus D, Pro B, Fayad L, Rodriguez A, Zelenetz AD. Sequential RCHOP and YTTRIUM-90 Ibritumomab Tiuxetan (RIT) is a highly effective regimen for High Risk Elderly Patients with Untreated DLBCL. Annals of Oncology 19(4):iv100, 2008.
127. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad L, Colffier B, Moschhauser F. Acitivity of Veltuzumab, a Second-Generation Humanized Anti-CD20 MAB, in Laboratory and Clinical Studies. Annals of Oncology 19(4):iv130, 2008.
128. Berkova Z, Maeng H, Wang S, Wang S, Wise J, Hawke D, Campbell M, Fayad L, Kwak L, Samaniego F. CD74 Associates with FAS and Inhibits FAS-Mediated Apoptotic Signaling. Annals of Oncology 19(4):iv169, 2008.
129. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in Combination with Rituximab is Effective with Manageable Toxicity in a Phase I/II study in Relapsed/Refractory Mantle Cell Lymphoma. Annals of Oncology 19(4):iv174, 2008.
130. Samaniego F, Fanale M, Pro B, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin Combined with Cyclophophamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lymphoma. Annals of Oncology 19(4):iv182, 2008.
131. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Annals of Oncology 19(4):iv214, 2008.
132. Wedgwood AR, Fanale M, Fayad LE, McLaughlin P, Hagemeister F, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood 110(11):71a, 2007.
133. Rodriguez MA, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Huang X, Durand JBE. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood 110(11):187B, 2007.
134. Fanale M, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma. Blood 110(11):198B, 2007.
135. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri I. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 110(11):149a, 2007.
136. Khouri I, Saliba R, Korbling M, Hosing C, Fayad LE, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up. Blood 110(11):150a, 2007.
137. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin P, Pro B, Wang M, Rodriguez MA, Hagemeister F, Macapinlac HA, Podoloff DA, Champlin RE, Khouri I. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 110(11):191a, 2007.
138. Pro B, Fayad LE, Romaguera JE, Fanale M, Younes A, Hagemeister F, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang NH. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11):1013A, 2007.
139. Wang M, Fayad LE, Hagemeister F, Neelapu S, Samuels B, Samanigo F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera JE. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110(11):755a, 2007.
140. Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad LE, Wedgwood A, Buglio D, Patterson T, Dubay M, Li Z, Martell RE, Ward MR, Bociek RG. Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood 110(11):756a, 2007.
141. Zhou X, Huen A, Teegala A, Ji Y, Fayad LE, Hagemeister F, Vadhan-Raj S. Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors. Blood 110(11):66B, 2007.
142. Fayad LE, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera JE, Rodriguez MA. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110, 2007.
143. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister F, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110, 2007.
144. Thomas D, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani F, Wierda W, Rodriguez MA, Fayad LE, O’Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL). Blood 110, 2007.
145. Wang S, Wang S, Maeng H, Young DP, Prakash OM, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109, 2007.
146. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, and Romaguera J.. A Phase I/II Study of Lenalidomide (Len) in Combination with Rituximab (R) in Relapsed/Refractory Mantle Cell Lymphoma (MCL) with Early Evidence of Efficacy. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 25(18s):[8030], 2007.
147. Huen A, Romaguera JE, Fayad LE, Teegala SR, Ji Y, and Vadhan-Raj S.. Increased Toxicity Associated with Delayed Clearance of Methothrexate (MTX) in Patients with Lymphoma Receiving High-Dose MTX. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):[19578], 2007.
148. Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, and Cabanillas F.. Predictive Value for Survival of a Risk Model of Two Serological Markers, Beta-2-Microglobulin (B2M) and Lactic Dehydrogenase (LDH), in Diffuse Large Cell Lymphoma (DLCL). J Clin Oncol 25(18s):10599, 2007.
149. Falchook GS, Dhillon N, Moulder S, Duvic M, Ng C, Hong D, Camacho L, Lim J, Wang M, Fayad L, and Kurzrock R.. Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):14087, 2007.
150. Lenihan DJ, Massey MR, Baysinger K, Steinert D, Fayad L, Yusuf SW, Chiu A, Durand A, and Yeh ET.. Early Detection of Cardiotoxicity During Chemotherapy Using Biomarkers. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19521, 2007.
151. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M, Horne H, Teoh N, Wegner WA, and Goldenberg DM.. Low Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Refractory or Recurrent NHL: Phase I/II Results. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8032, 2007.
152. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Kwak L, Romaguera J, and Rodriguez MA.. R-HCV AD/R-MTX-ARAC is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features: M.D. Anderson Experience in 40 Patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8058, 2007.
153. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, and Vadhan-Raj S.. Risk Factors for Neutropenic Fever in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Onco 25(18s):19616, 2007.
154. Zhou X, Teegala SR, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagemeister FB, and Vadhan-Raj S.. Risk Factors for Severe Anemia Requiring Red Blood Cell Transfusions in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19537, 2007.
155. Forero-Torres A, Cohen P, Cheson BD, Robinson KS, La Casce AS, Fayad L, Camacho ES, Williams ME, Van de Jagt RH, Friedberg JW.. A phase II study of Bendamustine for rituximab refractory B-cell Non-Hodgkin’s lymphoma. ESMO, 2006.
156. Kurzrock R, Voorhees P, Fayad L, Orlowsky R, Van Thee F, Furman R, Borghaei H, Zaki MH, Prabhakar U, Garay C.. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with hematology malignancies. J Clin Oncol 24(18s):664s, 2006.
157. Pro B, Fayad L, Romaguera J, Hagemeister FB, Samaniego F, McLauhglin P, Rodriguez AM, Kwak L, Walker P, Dang N.. A phase II of HCVDDoxil alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma. J Clin Oncol 24 (18s):103s, 2006.
158. Kornblau SM, Jackson CE, Worthing A, Faderl S, Beran M, Fayad L, Ravhandi-Kashani F, Borthakur G, Gale R, Vertovsek S.. A phase I trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101). J Clin Oncol 24 (18s):664s, 2006.
159. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister, F, and Fayad L.. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108(11):[2404], 2006.
160. Fayad L, Patel H, Verhoef G, Czuczmar M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, and Advani A.. Clinical Activity of the immunoconjugate CMC-544 in B-Cell malignancies: Cohort of a Phase I Study. Blood 108(11):[2711], 2006.
161. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster S, Dyer MJS, Petillon MO, Coleman M, Bahkti A, Horen H, Xu L, Teoh N, Wegener W, and Goldenberg DM.. Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. Blood 108(11):[2719], 2006.
162. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, and Kurzrock R.. CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) – Prelimi Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematolog Malignancies. Blood 108(11):[2728], 2006.
163. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, and Fanale M.. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108(11):[2742], 2006.
164. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, and Cabanilla F.. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108(11):[2749], 2006.
165. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera J, and Stromatt S.. Results of a Phase I/II Trial of Pixantrone in combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed Refractory Indolent Non-Hodkin’s Lymphoma (NHL). Blood 108(11):[2758], 2006.
166. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, kwak L, and Rodriguez MA.. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108(11):[2770], 2006.
167. Faderl S, Ferrajoli A, Wierda WG, O’Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning ML, and Keating MJ.. The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood 108(11):[2827], 2006.
168. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, kebriaei P, Ueno N, Qazilbash MH, McLaughlin P, Hagemeister FB, Younes A, Podoloff DA, and Champlin RE.. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed and Non-Hodgkin’s Lymphoma (NHL). Blood 108(11):[315], 2006.
169. Fayad L and Cannata J.. Adult Langerhans’ Cell Histiocitosis (LCH): A Single Institution Experience. Blood 108(11):[3890], 2006.
170. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S.. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108(11):[3994], 2006.
171. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, and Vadhan-Raj S.. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108(11):[4103], 2006.
172. Kadia T, Fayad L, Rodriguez MA, McLaughlin P, and Pro B.. Retrospective Review of Angiommunoblastic T-Cell Lymphoma: The MD Anderson Cancer Experience. Blood 108(11):[4690], 2006.
173. Samaniego F, Fayad L, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu S, Younes A, and Kwak L.. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood 108(11):[4722], 2006.
174. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Dubay M, Backstrom J, and Martell RE.. A Phase II Study of a Novel Oral Isotype-Selective Histone Deacetylase(HDAC) Inhibitor in Patients with Relapsed or Refractory Hodgkin Lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8000, 2006.
175. Cohen P, Cheson B, Friedberg J, Robinson KS, Foran J, Fayad L, Tulpule A, Bessudo A, van der Jagt R, Suster MS, Multani PS. The novel alkylator Bendamustine HCL is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. . J Clin Oncol 23(16S):576S, 2005.
176. Fayad L, Dang J, Keating M . Hodgkin’s disease variant of Richter’s syndrome, an update of the M. D. Anderson experience. . Ann Oncol 16(Suppl 5):v114, 2005.
177. Fayad L, Liebman J, Mediano M, Cohen G, Pro B, Romaguera J, Countouridis A, Lymboura M, Comis S, Laffranchi B . A phase I/II trial of pixantrone combined with fludarabine (FL), dexamethasone (DEX) and rituximab (FPD-R) for treatment of recurrent indolent B-cell non-Hodgkin’s lymphomas. . Ann Oncol 16(Suppl 5):v156, 2005.
178. Fayad L, Romaguera J, hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. . J Clin Oncol 23(16S):591S, 2005.
179. Georgakis G, Li Y, Rassidakis G, Fayad L, Medeiros L, Younes A . Therapeutic inhibition of heat schock protein-90 function in Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v215, 2005.
180. Jabbour E, Hosing C, Pro B, Khouri I, Fayad L . Positive Pre-transplant PET/Ga67 (Ga) predicts poor outcome in refractory and relapse Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v121, 2005.
181. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, Fayad LE. Pre transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). Proceedings ASCO. J Clin Oncol 23(16S):562S, 2005.
182. Khouri I, Saliba R, Lee M, Okoroji GJ, Fayad L, Acholonu S, Maadani F, Hosing C,Younes A, McLauhglin P, Champlin R . Transplant Lite with rituximab-containing conditioning regimens for Non-Hodgkin’s Lymphomas (NHL): An Update. . Ann Oncol 16(Suppl 5):v101, 2005.
183. McLaughlin P, Liu NS, Grimmm E, Fayad L, Hagemeister FB, Nunez G, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee BN, Reuben JM, Kwak L, Rodriguez MA . Rituximab plus GM-CSF (Leukineä) for Indolent Lymphoma. . Ann Oncol 16(Suppl 5):v68, 2005.
184. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros J, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F . Stage IV indolent Lymphoma: A randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab with interferon maintenance. . Ann Oncol 16(Suppl 5):v109, 2005.
185. Pro B, Cabanillas F, Fayad L . High-serum b2 microglobulin is an important independent prognostic factor for disease progression in patients with follicular lymphoma. . Ann Oncol 16(Suppl 5):v149, 2005.
186. Pro B, Leber B, Smith MR, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. A Phase II Trial of Oblimersen Sodium (G3139) plus Rituximab for Treatment of Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. . Ann Oncol 16(Suppl 5):v68, 2005.
187. Pro B, Smith MR, Leber B, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA . Phase II study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. J Clin Oncol 23(16S):587S, 2005.
188. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, MedeirosJ, Katz,R, Gagneja H, Samuels B, Cabanillas F . High rates of Failure-Free Survival (FFS) and Overall Survival (OS) in untreated Mantle Cell lymphoma(MCL) after Rituximab plus HyperCVAD (R-HCVAD) alternating with rituximab plus High-Dose Methotrexate-Cytarabine (R-M/A). . Ann Oncol 16(Suppl 5):v95, 2005.
189. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M . Safety and efficacy of single fixed dose pegfilgrastin (Neulasta) in chemotherapy regimens given every 14 days: Results of ABVD plus pegfilgrastin in patients with Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v196, 2005.
190. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, dang N, Samaniego F, Rodriguez M, Fayad L . Paclitaxel plus Topotecan plus Rituximab (TTR): An Effective Salvage Program for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma (NHL). Ann Oncol 16(Suppl 5):v101, 2005.
191. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N, et al . Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin’s lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenviroment. . Ann Oncol 16(Suppl 5):v196, 2005.
192. Younes A, Pro B, Fayad L, Dang N, Romaguera J . (Velcade) for the treatment of relapsed classical Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v210, 2005.
193. Khouri IF, Saliba RM, Lee MS, Okoroji GJ, Fayad L, Maadani F, Hosing C, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, and Champlin RE.. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Blood 106(11):[44] 19a, 2005.
194. Khouri IF, Saliba RM, Hosing CM, Acholonu SA, Fayad LE, Korbling MJ, Saenz C, Pro B, Samuels BI, de Lima MJ, Giralt SA, Younes A, McLaughlin P, and Champlin RE.. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). Blood 106(11):[48] 19a, 2005.
195. Friedberg JW, Cohen P, Cheson BD, Robinson KS, Forero-Torres A, Fayad L, La Casce AL, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver J, and Benaim E.. Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). Blood 106(11):[229] 70a, 2005.
196. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez A, Younes A, Wang M, and McLaughlin P.. Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood 106(11):[933] 274a, 2005.
197. Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Dang N, Goy A, Romaguera J, Pro B, Beasley V, Cabanillas F, and Rodriguez M.. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL). Blood 106(11):[941] 277a, 2005.
198. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Younes A, and Cabanillas F.. Phase II Study of Sphingosomal Vincristine in CHOP+/ – Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients. Blood 106(11):[943] 277a, 2005.
199. Tsimberidou AM, O’Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, and Keating MJ.. Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience. Blood 106(11):[976] 287a, 2005.
200. Younes A, Fayad L, Pro B, Goy A, Romaguera JE, Hagemeister FB, and McLaughlin P.. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. Blood 106(11):[1498] 431a, 2005.
201. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, and Medeiros J.. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood 106(11):[1499] 431a, 2005.
202. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy AH, Beasley V, and Kwak L.. High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A). Blood 106(11):[2446] 688a, 2005.
203. Thompson MA, Pro B, Sarris A, Hagemeister FB, Goy A, Bleyer A, Cabanillas F, Samaniego F, and Fayad LE.. Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. Blood 106(11):[2681] 753a, 2005.
204. Dang NH, McLaughlin P, Fayad L, Romaguera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, and Pro B.. Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3349] 936a, 2005.
205. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu S, Kwak L, and Fayad L.. Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3350] 936a, 2005.
206. Soriano AO, Thompson M, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L, Admirand JH, and Pro B.. Follicular Dendritic Cell Sarcoma (FDCS): A Rare and Incurable Disease. Blood 106(11):[3892], 2005.
207. Younes A, Fayad L, Romaguera JE, Pro B, and Wang M.. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study. Blood 106(11):[4790], 2005.
208. Camboni G, Fayad L, Tulpule A, Modiano M, Espina BM, Cabanillas F, Levine AM . A phase I/II of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL). . J Clin Oncol 23:578, 2004.
209. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodruiguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L . Interim Analysis of a Phase II study of Dinileukin Diftitox (ONTAK) for relapsed/refractory T-cell Non-Hodgkin’s lymphoma. . Blood 104(11):722a, 2004.
210. Fayad L, Liebmann J, Modiano M, Cohen GI, Pro B, Romaguera J, Davite C, Lymboura M, Comis S, Laffranchi B . Preliminary results of a Phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatments of patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. . Blood 104(11):373a, 2004.
211. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA . Update on a phase (ph) 2 tudy of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphoma (NHL). . J Clin Oncol 23:575, 2004.
212. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F . Sphingosomal Vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma (NHL): Follow-up of a phase II study. . J Clin Oncol 23:745, 2004.
213. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F . Sphingosomal Vincristine in CHOP +/- rituximab is a promising new treatment for patients with high-risk untreated aggressive non-Hodgkin’s lymphoma (NHL): Follow-up results of a phase II study. . Blood 104(11):234b, 2004.
214. Samaniego F, Wang S, Young D, Fayad L, Wang S . Simian Virus 40 DNA sequences in non-Hodgkin’s lymphoma. . J Clin Oncol 23:581, 2004.
215. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M . Long-term safety and efficacy of single administration of a fixed dose peffilgrastin (Neulasta) in inducing neutrophil count recovery after ABVD chemotherapy in patients with Hodgkin’s lymphoma. . Blood 104(11):245b, 2004.
216. Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros LJ, Lewis J, Srivastava P. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. . Proceedings of ASCO 22:2294, 2003.
217. Levine AM, Fayad LE, Tulpule A, Modiano M, Espina BM, Camboni G, Cabanillas F. Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL). . Blood 102(11):640a, 2003.
218. Younes A, Pro B, Goy A, Fayad L, Romaguera J. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Disease. Depletion of Benign B-Cells from HD Microenvironment by Rituximab May Enhance the Activity of Gemcitabine. . Blood 102(11):412a, 2003.
219. Younes A, Fayad LE, Romaguera JE, Pro B, Dang N, Wang M. Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after 170 Consecutive Doses of ABVD Chemotherapy in Patients with Hodgkin Lymphoma: Safety of Pegfilgrastim with q14-Day Chemotherapy Regimens. Blood 102(11):637a, 2003.
220. Younes A, McLaughlin P, Goy A, Medeiros LJ, Jones D, Fayad LE, Abruzzo L, Pro B. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease: A Novel Combination Program Targeting the Cancer Cells and the Microenvironment. . Blood 102(11):27a, 2003.
221. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L. Taxol Plus Topetecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgekin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. Blood 102(11):142a, 2003.
222. Pro B, Cabanillas F, Dang NH, Fayad LE, Goy A, McLaughlin P, Rodriguez MA, Romaguera JE, Samaniego F, Wu HH, Hess M, Gold DL, Hagemeister F. Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. . Blood 102(11):281b, 2003.
223. Khouri I, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayad LE, Couriel DR, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE. Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stme Cell Transplantation (ASCT) fro Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): The Impact of Histologies of follicular (FL) Origin. Blood 102(11):735a, 2003.
224. Levine A, Fayad L, Modiano M, Camboni G, Cabanillas F . Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma. . Exp Hematol 31(Suppl 1):110, 2003.
225. Levine AM, Fayad L, Modiano M, Camboni G, Cabanillas F . Phase I study of Pixantrone in BSHAP for relapsed non-Hodgkin’s Lymphoma. . Proceedings of the International Society of Experimental Hematology, France, 2003.
226. Dang N, Hagemeister F, Fayad LE, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Goy A, Wang M, Walker PL, Samuels B, Jones D, Rodriguez MA. Analysis of a Phase II Study of Denileukin Diftitox (ONTAK) for B and T-Cell Non-Hodgkins Lymphoma. . Blood 102(11):303b, 2003.
227. Liu NS, Grimm E, Poindexter N, Rodriguez MA, Hagemeister F, Pro B, Fayad LE, Lee BN, Reuben JM, McLaughlin P. [1495] Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. . Blood 102(11):411a, 2003.
228. Pro B, Smith MR, younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Genasense (BCL-2 Antisense) plus Rituximab is active in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma. . Blood, 2003.
229. Liu Q, Fayad LE, Hagemeister F, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Blood 102(11):398a, 2003.
230. Younes A, Pro B, Hagemeister F, Rodriguez MA, McLaughlin P, Fayad LE, Goy A, Cabanillas F. Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. Blood 100:2868, 2002.
231. Younes A, Fayad L, Pro B, Romaguera J, Ha CS, Wilder R. Safety and Efficacy of Prophylactic Pegfilgrastim in Patients with Hodgkin Disease Receiving ABVD Chemotherapy. . Blood 100:4179, 2002.
232. Younes A, Fayad LE, McLaughlin P, Goy A, Romaguera J, Rodriguez MA, Hagemeister F, Samaniego F, Pro B, Medeiros J, Ha C, Wilder R, Seifert A. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease. . Blood 100:4774, 2002.
233. Younes A, McLaughlin P, Pro B, Hagemeister F, Fayad LE, Romaguera JE. Activity of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma. . Blood 100:4722, 2002.
234. Pro B, Romaguera J, Macapinlac H, Fayad LE, Dang N, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff D, Hagemeister F, Younes A, Cabanillas F. Positron Emission Tomography Using Fluorodeoxyglucose but Not Gallium-67 Scintigraphy Is a Sensative Imaging Modality in the Staging of Mantle Cell Lymphoma. Blood 100:3041, 2002.
235. Hagemeister F, McLaughlin P, Clemons M, Rodriguez MA, Fayad L, Romaguera J, Pro B, Goy A, Samaniego F, Dang NH, Cabanillas F. FND (Fludarabine, Mitoxantrone, Dexamethasone)- R(Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. Blood 100:4760, 2002.
236. Khouri IF, Saliba R, Hosing C, Kôrbling M, Younes A, Romaguera J, Fayad L, Cabanillas F, Champlin RE. Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma. . Annals of Oncol 13(Suppl 2):262, 2002.
237. Rodriguez MA, Sarris A, East K, Dang N, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. A Phase II study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): A Safe and Effective Combination. . Blood 100:338, 2002.
238. Romaguera J, Cabanillas F, Dang N, Goy A, Fayad LE, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros LJ, Gagneja HK. Mantle Cell Lymphoma (MCL). Update on results after R-HCVAD without stem cell transplant (SCT). Annals of Oncol 13(Suppl 2):024, 2002.
239. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F . Addition of Rituximab to Taxol plus Topotecan (TTR) improves response rate and complete remission rate in patients with relapsed/refractory aggressive B-cell lymphoma. . Annals of Oncol 13(Suppl 2):246, 2002.
240. Fayad L, Estey E, Thomas D, O’Brien S, Keating M, Koller C, Pierce S, Talpaz S, Boyer K, Freireich E, Kantarjian H, Kurzrock R. Treatment of Hairy Cell Leukemia with Cladribine (2CDA): Long-term follow-up at M.D. Anderson Cancer Center. Blood 98(11), 2001.
241. Fayad L, Romaguera J, Pro B, Younes A, Dang N, Samaniego F, Garcia P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanillas F, P Rodriguez. Primary Mediastinal Large B-Cell lymphoma (PMLBL): Poor prognosis in patients with extranodal sites. Blood 98(11):Part I of II, 2001.